CME Session
Hybrid Session
Kiran Virdee, RN CCRN-K
Memorial Sloan Kettering Cancer Center
Disclosure: Disclosure(s): No financial relationships to disclose
Elizabeth Wulff-Burchfield, MD
University of Kansas Medical Center
Disclosure: Disclosure(s): Advisory Board: Aveo Oncology (Terminated, November 30, 2021); BMS (Terminated, November 30, 2021); Exelixis (Terminated, November 30, 2021); Janssen (Terminated, November 30, 2021)
Contract Research: Acer Therapeutics (Ongoing)
Grant funding: Pfizer Global Medical Grants (Terminated, March 31, 2022)
Non-CE Consulting: Astellas/Medivation (Ongoing); BMS (Ongoing)
Ownership Interest: A family member has owned stocks of the Commercial Entity: Nektar (Ongoing)
Ownership Interest: I own stocks of the Commercial entity: Immunomedics (Terminated, September 30, 2020)
Afreen Shariff, MD, MBBS
Duke University
Cary, North Carolina, United States
Disclosure: Disclosure(s): Non-CE Consulting: Bristol Meyers Squibb (Ongoing)
Non-CE Speakers Bureau: Merck (Ongoing)
Michael L. Dougan, MD, PhD
Massachusetts General Hospital and Harvard Medical School
Boston, Massachusetts, United States
Disclosure: Disclosure(s): Non-CE Consulting: Aditum (Ongoing); Foghorn (Ongoing); Mallinckrodt (Ongoing); Neoleukin Therapeutics (Ongoing)